Research Department, The Social Insurance Institution, Turku, Finland.
Eur J Clin Pharmacol. 2011 Jan;67(1):73-7. doi: 10.1007/s00228-010-0884-4. Epub 2010 Aug 31.
The aim of this study was to estimate the 1-year prevalence of levothyroxine-treated hypothyroidism in Finland.
Data on all individuals who had regularly purchased levothyroxine sodium tablets during 2007 were retrieved from the nationwide Finnish Drug Prescription Database. The prevalence rates and 95% confidence intervals were calculated per 100 individuals assuming a Poisson distribution.
In total, 189,027 individuals (84% female) were identified as using levothyroxine tablets, which translated into a 1-year prevalence of hypothyroidism of 3.6%. The disease was notably more common in females (5.9%) than in males (1.2%), with a gender prevalence rate ratio (PRR) of 4.5. Prevalence increased with age. A comparison of five university hospital districts revealed that the prevalence rates were fairly stable regionally, with the lowest rate being 3.1% and the highest 4.4%; the regional PRR was 1.3.
To the best of our knowledge, this nationwide prescription study includes the largest population of reported levothyroxine users to date. This comprehensive data justifies estimating the gender- and age-specific prevalence of hypothyroidism in Finland.
本研究旨在估计芬兰左旋甲状腺素治疗性甲状腺功能减退症的 1 年患病率。
从全国性的芬兰药物处方数据库中检索了所有在 2007 年期间定期购买左甲状腺素钠片的个体的数据。假设泊松分布,按每 100 人计算患病率和 95%置信区间。
共确定了 189027 名(84%为女性)使用左甲状腺素片的个体,这意味着甲状腺功能减退症的 1 年患病率为 3.6%。该疾病在女性(5.9%)中明显比男性(1.2%)更为常见,性别患病率比(PRR)为 4.5。患病率随年龄增长而增加。对五个大学医院区的比较表明,该疾病的患病率在区域间相对稳定,最低为 3.1%,最高为 4.4%;区域 PRR 为 1.3。
据我们所知,这项全国性的处方研究包括迄今为止报告的最大左甲状腺素使用者人群。这些全面的数据证明可以合理估计芬兰甲状腺功能减退症的性别和年龄特异性患病率。